CMN Weekly (15 September 2023) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Sep. 15, 2023
News

#CRISPRMED24

Top picks

Research

Industry

Detection

Reviews

Conferences and meetings

  • You can register as an early bird until September 22 for the 4th Annual CRISPR 2.0 Congress in Boston on November 28-30. The conference focuses on 1) Next-generation developments and therapeutic applications of CRISPR technologies, 2) Innovative in vivo and ex vivo CRISPR delivery approaches, and 3) Overcoming key translational limitations facing drug developers seeking to enter the clinic.

Commentaries

  • An article in Technology Networks outlines the potential for groundbreaking discoveries with CRISPR screening. The paper considers various platforms to modulate gene expression, experimental design, current challenges and the potential of CRISPR-Cas systems to understand and treat diseases, from cancers and congenital disorders to overcoming the growing prevalence of antimicrobial resistance.

Huh, heh, wow

  • French researchers propose using Wikipedia to study the accumulation and transfer of scientific knowledge. They analyzed Wikipedia articles on CRISPR gene editing, demonstrating how they document the evolution of scientific discoveries into societal revolutions. The method leverages Wikipedia as a free and digital archive to track knowledge growth and its translation into public discourse, complementing traditional research methods.

News from CRISPR Medicine News

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (15 September 2023) - Your Weekly CRISPR Medicine News
News: CMN Weekly (15 September 2023) - Your Weekly CRISPR Medicine News
CLINICAL TRIALS
Systemic Lupus Erythematosus SLE, (NCT06255028)
Sponsors:
Century Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Chronic Granulomatous Disease, CGD, (NCT06325709)
Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT06287099)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine